The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

The BEACON study used de-identified data from the Tempus Database, assessing IB6 expression via immunohistochemistry.

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...